• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2021年分子遗传病理学新进展：实体瘤与NGS检测板选择

What's new in molecular genetic pathology 2021: solid tumors and NGS panel selection.

作者信息

Chen Guoli, Tsang Patricia C

机构信息

Geisinger Medical Laboratories, Geisinger Health, Danville and Wilkes-Barre, PA, USA.

出版信息

J Pathol Transl Med. 2021 Nov;55(6):421-422. doi: 10.4132/jptm.2021.09.01. Epub 2021 Nov 12.

DOI:10.4132/jptm.2021.09.01
PMID:34788978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8601954/
Abstract

The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue.

摘要

精准医学的关键在于分子遗传学和基因组检测。分子生物标志物对于精准诊断以及预测治疗反应至关重要，这能使癌症患者接受个性化和靶向治疗。以下是下一代测序（NGS） panel 选择以及肺、消化系统、甲状腺和软组织实体瘤分子检测当前考量因素的要点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc18/8601954/79783a5922af/jptm-2021-09-01f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc18/8601954/79783a5922af/jptm-2021-09-01f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc18/8601954/79783a5922af/jptm-2021-09-01f1.jpg

相似文献

1
What's new in molecular genetic pathology 2021: solid tumors and NGS panel selection.2021年分子遗传病理学新进展：实体瘤与NGS检测板选择
J Pathol Transl Med. 2021 Nov;55(6):421-422. doi: 10.4132/jptm.2021.09.01. Epub 2021 Nov 12.
2
Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.基于新一代测序的临床测序：迈向实体瘤的精准医学。
Int J Clin Oncol. 2019 Feb;24(2):115-122. doi: 10.1007/s10147-018-1375-3. Epub 2018 Dec 4.
3
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.将下一代测序（NGS）纳入亚洲非小细胞肺癌（NSCLC）人群的实用性：可操作改变的增量收益和成本效益分析。
Lung Cancer. 2020 Jan;139:207-215. doi: 10.1016/j.lungcan.2019.11.022. Epub 2019 Nov 26.
4
Clinical applications of next-generation sequencing in colorectal cancers.下一代测序在结直肠癌中的临床应用。
World J Gastroenterol. 2013 Oct 28;19(40):6784-93. doi: 10.3748/wjg.v19.i40.6784.
5
Multiplex gene-panel testing for lung cancer patients.肺癌患者的多重基因panel 检测。
Pathol Int. 2020 Dec;70(12):921-931. doi: 10.1111/pin.13023. Epub 2020 Sep 21.
6
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.前瞻性临床整合基于扩增子的下一代测序方法，以选择晚期非小细胞肺癌患者进行基于基因型的治疗。
Clin Lung Cancer. 2018 Jan;19(1):65-73.e7. doi: 10.1016/j.cllc.2017.06.008. Epub 2017 Jun 23.
7
Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.临床和经济价值的遗传测序个性化治疗的非小细胞肺癌。
Clin Lung Cancer. 2020 Nov;21(6):477-481. doi: 10.1016/j.cllc.2020.05.029. Epub 2020 Jun 5.
8
Clinical Next Generation Sequencing for Precision Medicine in Cancer.用于癌症精准医疗的临床下一代测序技术
Curr Genomics. 2015 Aug;16(4):253-63. doi: 10.2174/1389202915666150511205313.
9
Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.游离循环肿瘤DNA补充组织活检用于识别可靶向突变：对精准医学的意义及结果协调的考量
Lung Cancer. 2017 Sep;111:135-138. doi: 10.1016/j.lungcan.2017.06.015. Epub 2017 Jun 23.
10
Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.在常规实验室实践中实施下一代测序技术进行体细胞突变检测。
Pathology. 2018 Jun;50(4):389-401. doi: 10.1016/j.pathol.2018.01.005. Epub 2018 May 8.

本文引用的文献

1
Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm.横纹肌肉瘤：先进分子方法如何塑造诊断和治疗模式
Pediatr Dev Pathol. 2021 Sep-Oct;24(5):395-404. doi: 10.1177/10935266211013621. Epub 2021 Jun 9.
2
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.曲妥珠单抗-德鲁替康（DS-8201）治疗人表皮生长因子受体 2（HER2）表达的转移性结直肠癌（DESTINY-CRC01）患者：一项多中心、开放标签、Ⅱ期临床试验。
Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4.
3
Liquid biopsy enters the clinic - implementation issues and future challenges.
液体活检进入临床——实施问题与未来挑战。
Nat Rev Clin Oncol. 2021 May;18(5):297-312. doi: 10.1038/s41571-020-00457-x. Epub 2021 Jan 20.
4
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.非小细胞肺癌的分子检测与靶向治疗：现状与展望
Crit Rev Oncol Hematol. 2021 Jan;157:103194. doi: 10.1016/j.critrevonc.2020.103194. Epub 2020 Dec 11.